Probes For Detection Of Specific Nucleotide Sequences Or Primers For The Synthesis Of Dna Or Rna Patents (Class 536/24.3)
  • Patent number: 10190180
    Abstract: Disclosed are nucleic acid oligomers for amplifying one or more selected regions of HCV nucleic acid. Also disclosed are methods for specific amplification and characterization of HCV nucleic acid using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: January 29, 2019
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Reinhold B. Pollner, Shyun-Shyun Lee
  • Patent number: 10017185
    Abstract: A method is provided for damping electromechanical oscillations in an electromechanical system including at least one electric machine operable with an angular speed and a phase of the angular speed being coupled to at least one torque load and producing an electromotive force. The method includes deriving actual values of the electromotive force and adjusting the phase of the angular speed, based on the derived actual values of the electromotive force, in a direction in which an oscillatory behavior of the electric machine is reduced.
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: July 10, 2018
    Assignee: Volvo Technology Corporation
    Inventor: Johan Lindberg
  • Patent number: 10006084
    Abstract: A method including contacting a tissue or cellular sample with a reagent including an evaporation reducing agent(s) having the general formula X1—R—X2, wherein R is an alkyl, alkenyl, alkynyl or an aromatic moiety of 1 or more carbon atoms that may be substituted with an oxygen, nitrogen or sulfur and X1 and X2 are independently selected to be moiety that is susceptible to hydrogen bonding and processing the tissue or cellular sample. A reagent used in the processing of a tissue or cellular sample with the reagent containing an evaporation reducing agent.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: June 26, 2018
    Assignee: Sakura Finetek U.S.A., Inc.
    Inventors: Douglas T. Yamanishi, Clifford Hom, Amit D. Shah
  • Patent number: 10001391
    Abstract: An electronic device comprises a sensor comprising first and second electrodes, with the sensor being configured for a first acoustic displacement due to input acoustic pressure; circuitry configured to measure a charge between the first and second electrodes due to the input acoustic pressure and to apply a voltage to cause a second acoustic displacement of the sensor that is out of phase with the first acoustic displacement, with the applied voltage further causing a charge to develop across the sensor, and with the first and second acoustic displacements causing an increase in damping in a resonance frequency of the sensor, relative to damping of the resonance frequency of the sensor prior to applying the voltage; and a passive electronic component configured to cancel out the charge developed across the sensor due to the applied voltage.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: June 19, 2018
    Assignee: Vesper Technologies Inc.
    Inventors: Robert J. Littrell, Karl Grosh
  • Patent number: 9959362
    Abstract: Techniques are described for creating a context-aware landing page. A context-aware landing page is capable of dynamically updating its tiles to include content tiles which are related to a received triggering event. The triggering event can be received from a business context source. When the triggering event is received, a weighting table that contains a plurality of content tiles can be retrieved. The method can then select one or more content tiles to include in the context-aware landing page. The selection of the one or more content tiles can depend on the triggering event.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: May 1, 2018
    Assignee: SAP SE
    Inventor: Shan Jiang
  • Patent number: 9909175
    Abstract: The present invention relates to methods for determining the sequence bias of a sequencing technique. Furthermore, the invention relates to methods to reduce or enhance sequence bias during sequencing of nucleic acids via techniques involving adaptor ligations. Specifically the method relates to use of a degenerate RNA sequence to analyze sequence bias when generating small RNA libraries, and to the use of modified adaptors for cloning of small RNAs with degenerate or specific sequences to reduce or enhance sequencing bias, as well as various nucleic acid molecules relating thereto or derived therefrom.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: March 6, 2018
    Assignee: UNIVERSITY OF EAST ANGLIA
    Inventors: Karim Sorefan, Tamas Dalmay, Vincent Moulton, Helio Ernesto Coronel Machado Pais
  • Patent number: 9896719
    Abstract: A new class of nucleic acid substrates for AP endonucleases and members of the glycosylase/lyase family of enzymes is described. Representatives of each family, the enzymes Nfo and fpg, respectively, cleave nucleic acid backbones at positions in which a base has been replaced by a linker to which a variety of label moieties may be attached. The use of these synthetic substrates embedded within oligonucleotides is of utility in a number of applications.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: February 20, 2018
    Assignee: Alere San Diego Inc.
    Inventors: Olaf Piepenburg, Niall A. Armes
  • Patent number: 9889226
    Abstract: Disclosed are photocrosslinked hyaluronic acid (HA) derivatives consisting of HA, a bifunctional polyethylene glycol (PEG) spacer which is triethylene glycol, and a photoreactive compound selected from a coumarin derivative and propiophenone.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: February 13, 2018
    Assignee: FIDIA FARMACEUTICI S.P.A.
    Inventors: Monica Campisi, Ottorino De Lucchi, Riccardo Beninatto, Giuseppe Borsato
  • Patent number: 9889422
    Abstract: Methods and compositions are disclosed relating to the localization of nucleic acids to arrays such as silane-free arrays, and of sequencing the nucleic acids localized thereby.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: February 13, 2018
    Assignee: ILLUMINA CAMBRIDGE LIMITED
    Inventors: Mark Edward Brennan Smith, Andrea Sabot, Isabelle Marie Julia Rasolonjatovo, Jean-Ernest Sohna Sohna, Adrian Martin Horgan, Harold Philip Swerdlow
  • Patent number: 9845507
    Abstract: Provided herein are methods for the detection of genetic mutations associated with cancer, particularly in the KIT gene.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: December 19, 2017
    Assignee: SYSMEX CORPORATION
    Inventors: Johannes Fredebohm, Frank Diehl, Frank Holtrup, Daniel Mehnert
  • Patent number: 9834439
    Abstract: The present invention relates generally to programming of biomolecular self-assembly pathways and related methods and constructs for self-assembly of prescribed two and three-dimensional structures.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: December 5, 2017
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Peng Yin, Niles A. Pierce
  • Patent number: 9758834
    Abstract: The application describes methods for diagnosing subjects with leukemia by detecting fusion genes associated with the onset of leukemia.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: September 12, 2017
    Assignee: NanoString Technologies, Inc.
    Inventors: Philippa Jane Webster, Richard Kemble Boykin, Jeannette Nussbaum
  • Patent number: 9593374
    Abstract: Disclosed is a method for quantitative determination of CK-19 mRNA positive cells in a biological sample. The method can be used, for instance, with peripheral blood to detect cancer in a patient. In one embodiment, the method can be used to detect the cancer before initiation of adjuvant treatment, thereby providing information about therapeutic efficacy. Practice of the invention method is sensitive, reliable, and easy to perform.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: March 14, 2017
    Inventors: Lianidou Evriklia, Aliki Stathopoulou, Dimitrios Mavroudis, Vasileios Georgoulias
  • Patent number: 9528163
    Abstract: The present disclosure relates to oligonucleotide sequences for amplification primers and their use in performing nucleic acid amplifications of HCV, in particular regions that encode the NS3 polypeptide. In some embodiments the primers are used in nested PCR methods for the detection or sequencing of HCV NS3. The oligonucleotide sequences are also provided assembled as kits that can be used to amplify and detect or sequence HCV NS3.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: December 27, 2016
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Arejas Uzgiris, Sunil Pandit, Lance Palmer
  • Patent number: 9469867
    Abstract: A new class of nucleic acid substrates for AP endonucleases and members of the glycosylase/lyase family of enzymes is described. Representatives of each family, the enzymes Nfo and fpg, respectively, cleave nucleic acid backbones at positions in which a base has been replaced by a linker to which a variety of label moieties may be attached. The use of these synthetic substrates embedded within oligonucleotides is of utility in a number of applications.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: October 18, 2016
    Assignee: Alere San Diego, Inc.
    Inventors: Olaf Piepenburg, Niall A. Armes
  • Patent number: 9393309
    Abstract: A method for preparing a hydrogel composed substantially only of nucleic acids. Further. a nucleic acid sol-like composition for producing a nucleic acid gel without requiring the use of any nucleic acid ligase, wherein the composition comprises at least two nucleic acid monomers which are partly complementary to each other and are independently selected from the group consisting of a nucleic acid, a nucleic acid derivative, a modified nucleic acid, a compound capable of binding to a nucleic acid in a complementary manner and a mixture thereof, one of the nucleic acid monomers has a moiety that constitutes a cohesive protruding end and a complementary nucleotide sequence moiety that can bind to at least one of the other nucleic acid monomers to form a double strand, and the composition contains no nucleic acid ligase. Still further, a nucleic acid gel produced using the sol-like composition.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: July 19, 2016
    Assignee: Kyoto University
    Inventors: Makiya Nishikawa, Yuki Takahashi, Yoshinobu Takakura
  • Patent number: 9359616
    Abstract: Provided herein is a synthetic or isolated polynucleotide encoding a mammalian 18S rRNA that is resistant to pactamycin. The pactamycin-resistance is conferred by one or more single residue substitutions in the 18S rRNA sequence; a fragment thereof harboring said substitutions; a complementary sequence thereto; or a substantially identical sequence of the foregoing. Related systems, methods and kits are also described.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: June 7, 2016
    Assignee: The Scripps Research Institute
    Inventors: Vincent P. Mauro, Luke Burman, Gerald M. Edelman
  • Patent number: 9234241
    Abstract: The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: January 12, 2016
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Francis Barany, George Barany, Robert P. Hammer, Maria Kempe, Herman Blok, Monib Zirvi
  • Patent number: 9040493
    Abstract: The present invention relates to oligomer compounds (oligomers) for the treatment and prevention of acute myeloid leukemia, which target GLI2 mRNA in a cell, leading to reduced expression of GLI2.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: May 26, 2015
    Assignee: Santaris Pharma A/S
    Inventors: Yixian Zhang, Zhengxing Qu
  • Patent number: 9040287
    Abstract: The present invention provides molecular biosensors capable of signal amplification, and methods of using the molecular biosensors to detect the presence of a target molecule.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: May 26, 2015
    Assignees: Mediomics, LLC, Saint Louis University
    Inventors: Yie-Hwa Chang, Ling Tian, Tomasz Heyduk
  • Patent number: 9040496
    Abstract: The present invention relates to the field of cardiology. More specifically, the present invention provides methods and compositions for inducing proliferation of cardiomyocytes. In a specific embodiment, a method for inducing proliferation of cardiomyocytes comprises the step of administering an effective amount of an ALMS1 inhibitor.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: May 26, 2015
    Assignee: The Johns Hopkins University
    Inventors: Daniel Philip Judge, Peter Andersen, Lincoln Takura Shenje
  • Publication number: 20150141635
    Abstract: A composition comprising an oligonucleotide having the structure 5?-Y1-L1-X-L2-Y2-3?. Y1 comprises a sequence of one or more DNA or RNA nucleotides, including a first nucleotide N1 having a 3? phosphate covalently linked to L1. Y2 comprises a sequence of one or more DNA or RNA nucleotides, including a second nucleotide N2 having a 5? phosphate covalently linked to L2. L1 and L2 each independently are a direct bond or a C1-C7 alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, or alkoxyl group. X is R1 is a hydrogen or a C1-C8 alkyl. M is a label or ligand comprising a fused polycyclic aromatic moiety.
    Type: Application
    Filed: December 20, 2014
    Publication date: May 21, 2015
    Inventors: Scott Rose, Mark A. Behlke, Richard Owczarzy, Joseph A. Walder, Derek M. Thomas, Michael R. Marvin
  • Patent number: 9035035
    Abstract: The invention describes new structures of the nucleotide conjugates (nuc-macromolecules) comprising at lease one nucleotide moiety coupled to at least one macromolecular compound via a short linker. These conjugates can be used as substrates for various kinds of polymerizing enzymes in the enzymatic synthesis of nucleic acids. In particular, these compounds can be used for labeling nucleic acids.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: May 19, 2015
    Assignee: GENOVOXX GMBH
    Inventors: Dmitry Cherkasov, Englbert Bäuml
  • Patent number: 9034837
    Abstract: The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: May 19, 2015
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Elisabeth S. Hildebrandt-Eriksen, Andreas Petri, Sakari Kauppinen, Niels Abrahamsen, Robert Eldon Lanford
  • Publication number: 20150133313
    Abstract: The present invention relates to a method for identifying the variety of a hop by using an identification marker comprising at least one single nucleotide polymorphism that differs among varieties, and a method for preparing said identification marker. The present invention also provides a primer or a probe to be used in the method for identifying the variety of a hop, and a nucleic acid of a region including said identification marker. The present invention further provides a method for detecting the intrusion of different varieties in a hop sample.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 14, 2015
    Inventors: Hiromasa Yamauchi, Susumu Furukubo
  • Patent number: 9029084
    Abstract: A polynucleotide primer comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 1 to 18, 21 to 45 or 74 to 77.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: May 12, 2015
    Assignee: Qiagen Manchester Limited
    Inventors: David Mark Whitcombe, Nicola Jo Thelwell, Paul Francis Ravetto
  • Patent number: 9029103
    Abstract: Provided herein is a method for sequencing a polynucleotide molecules. The method includes the steps of providing a plurality of polynucleotide molecules attached to a surface, wherein a first portion of each polynucleotide molecule is attached to a first location of the surface and a second portion of each polynucleotide molecule is attached to a second location of the surface, the relative proximity of the first and second locations being correlated with the probability that the first and second portions are paired, separating the first and second portions of the polynucleotide molecules on the surface, determining the sequences of the first and second portions of the polynucleotide molecules and comparing the relative proximities and the sequences to determine which first and second portions are paired and to determine the sequence of the target polynucleotide molecules.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: May 12, 2015
    Assignee: Illumina Cambridge Limited
    Inventors: Roberto Rigatti, Niall Anthony Gormley, Jonathan Mark Boutell
  • Patent number: 9029086
    Abstract: A method for detecting analyte in a sample comprises: (a) contacting said sample with at least one set comprising a cassette oligonucleotide and first, second, third and fourth proximity probes, which probes each comprise an analyte-binding domain and a nucleic acid domain and can simultaneously bind to the analyte, the nucleic acid domains of said first and third proximity probes being complementary in a first overlap region and the nucleic acid domains of said second and fourth proximity probes being complementary in a second overlap region; and said cassette oligonucleotide being complementary to the nucleic acid domain of said third proximity probe in a third overlap region and to the nucleic acid domains of said fourth proximity probe in a fourth overlap region; (b) allowing the overlap regions of said proximity probes and said cassette oligonucleotide to hybridise; and (c) detecting said hybridisation. A kit is for performing the method.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: May 12, 2015
    Inventor: Masood Kamali Moghaddam
  • Patent number: 9023820
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: May 5, 2015
    Assignee: Protiva Biotherapeutics, Inc.
    Inventors: Marcia MacDonald, Amy C. H. Lee, Ian MacLachlan
  • Patent number: 9023824
    Abstract: The invention relates to a composition for angiogenesis inhibition comprising a peroxidasin inhibitor as an effective ingredient, and more particularly, to a method of screening angiogenesis inhibitor, which includes steps of treating a test agent, and analyzing peroxidasin gene expression or protein activity, and comparing peroxidasin gene expression or protein activity between a case treated with the test agent and a case not treated with the test agent. Accordingly, since the inhibitor of the peroxidasin expression or protein activity according to the present invention can effectively inhibit migration, proliferation and tube formation of endothelial cells, the inhibitor can be effectively used for preventing or treating a variety of diseases or conditions of the diseases derived from abnormal regulation of angiogenesis.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: May 5, 2015
    Assignee: Catholic University Industry Academic Cooperation Foundation
    Inventors: Young Ae Joe, Hyun Kyung Kim
  • Patent number: 9017938
    Abstract: This invention concerns the use of MicroRNA-199b-5p in medical and diagnostic fields. Particularly, this invention concerns the use of the miR199b-5p in the anti-cancer therapy and as a histophatological and metastasis marker.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: April 28, 2015
    Assignee: Advanced Accelerator Applications
    Inventor: Massimo Zollo
  • Patent number: 9018188
    Abstract: The present invention relates to microRNAs (miRNAs) that are associated with obesity. The present invention is directed to methods, compounds, and compositions for preventing and treating obesity, as well as related diseases, using a microRNA inhibitor.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: April 28, 2015
    Assignee: Ottawa Hospital Research Institute
    Inventors: Michael A. Rudnicki, Hang Yin
  • Patent number: 9017971
    Abstract: The invention provides improved methods for investigating nucleic acid sequences, wherein at least one additional probe is used which is specific for a (pseudo)gene variant of a target nucleic acid.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: April 28, 2015
    Assignee: Stichting Sanquin Bloedvoorziening
    Inventors: Taco Willem Kuijpers, Martin de Boer
  • Patent number: 9017973
    Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: April 28, 2015
    Assignee: Intelligent BioSystems, Inc.
    Inventors: Steven Gordon, Jerzy Olejnik
  • Patent number: 9017972
    Abstract: The present invention relates to a method, in particular an in vitro method for identifying FoxP3-positive CD25+CD4+ regulatory T cells of a mammal, comprising analyzing the methylation status of at least one CpG position in the FOXP3 gene, in particular its “upstream” regulatory regions, and in particular the promoter and the TSDR region of the gene foxp3, wherein a demethylation to at least 90% of at least one CpG in the sample as analyzed is indicative for a FoxP3-positive CD25+CD4+ regulatory T cell, and the use of said DNA-methylation analysis of the gene of the transcription factor FoxP3 for a detection and quality assurance and control of regulatory T cells. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: April 28, 2015
    Inventor: Ivana Türbachova
  • Patent number: 9012718
    Abstract: The present invention relates to a mutated nucleic acid sequence of a delta-12 oleate desaturase enzyme (FAD2)—encoding nucleic acid from a Cruciferae plant, wherein said mutated nucleic acid sequence comprises the non-conservative mutation of at least one nucleotide of at least one codon representing an amino acid selected from the group consisting of: —the amino acid at position 259 of the amino acid sequence of said FAD2, —the amino acid at position 216 of the amino acid sequence of said FAD2, —the amino acid at position 90 of the amino acid sequence of said FAD2, —the amino acid at position 116 of the amino acid sequence of said FAD2, —the amino acid at position 276 of the amino acid sequence of said FAD2.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: April 21, 2015
    Assignee: Institut National de la Recherche Agronomique (INRA)
    Inventors: Cyril Falentin, Michel Bregeon, Marie Odile Lucas, Michel Renard
  • Patent number: 9012139
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of Dystrophin family. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DMD family.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: April 21, 2015
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 9012419
    Abstract: Disclosed are compositions and methods for regulating eosinophils.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: April 21, 2015
    Assignee: University of Utah Research Foundation
    Inventors: Lori A. Wagner, Katrin Szardenings, Gerald J. Gleich, Tarek Aboul-Fadl Mohamed
  • Patent number: 9012426
    Abstract: The present invention relates to an anti-angiogenic composition, and more particularly, to a pharmaceutical anti-angiogenic composition including a microRNA-382 inhibitor. The inventors of the present invention have confirmed that microRNA-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis induced in a low oxygen environment. Therefore, the pharmaceutical composition of the present invention inhibits microRNA-382 and thus inhibits angiogenesis and cell proliferation, and is expected ultimately to be valuably used in the treatment of cancer.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: April 21, 2015
    Assignee: Kyungpook National University Industry—Academic Cooperation Foundation
    Inventor: You Mie Lee
  • Patent number: 9012142
    Abstract: A method for detecting the presence of a target nucleotide sequence in a sample of DNA is described herein in which a test sample comprising single stranded DNA is exposed to a DNA probe and a nicking endonuclease under conditions that would permit sequence-specific hybridization of the probe to a complementary target sequence. The probe comprises a sequence complementary to the target sequence to be detected and this sequence also includes a recognition sequence for the nicking endonuclease. If the sample contains the target sequence, the probe hybridizes to the target and is cleaved by the nicking endonuclease, which leaves the target intact. Observing the presence of probe cleaved by the nicking endonuclease indicates the presence of the target nucleotide sequence in the sample of DNA.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: April 21, 2015
    Assignee: Georgetown University
    Inventors: Mark Danielsen, Eugene A. Davidson, Kenneth L. Dretchen, Traci K. Pals
  • Patent number: 9012144
    Abstract: The invention provides methods for sequencing a polynucleotide comprising stopping an extension cycle in a sequence by synthesis reaction before the reaction has run to near or full completion.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: April 21, 2015
    Assignee: Fluidigm Corporation
    Inventors: Stanley Lapidus, Philip Richard Buzby, Timothy Harris
  • Publication number: 20150105298
    Abstract: The disclosure relates to in situ hybridization probes for the detection of target nucleic acid sequences within a sample and methods of making and using the same. The in situ hybridization probes of the current disclosure include a plurality of nucleic acid elements capable of selectively hybridizing to at least a portion of a nucleic acid of interest and/or other nucleic acid elements of the in situ hybridization probe, which enable the detection of a target nucleic acid. The current disclosure also relates to kits which incorporate the in situ hybridization probe compositions of the instant disclosure.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Applicant: The Research Foundation for The State University of New York
    Inventor: Kevin Czaplinski
  • Patent number: 9006200
    Abstract: The invention relates to microRNA mimics, corresponding to the miR-15/107 family, and to methodology for using microRNA mimics to treat malignant pleural mesothelioma (MPM) by restoring regulation of the expression of target genes of the miR-15/107 family in MPM tumor cells.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 14, 2015
    Assignee: Asbestos Diseases Research Foundation
    Inventors: Glen Reid, Nico van Zandwijk
  • Patent number: 9005892
    Abstract: The present invention relates to methods and reagents for detecting analytes, e.g. nucleic acids. The new methods and reagents allow a simple and sensitive detection even in complex biological samples.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: April 14, 2015
    Assignee: Baseclick GmbH
    Inventors: Thomas Carell, Anja Schwögler, Glenn A. Burley, Johannes Gierlich, Mohammad Reza Mofid
  • Patent number: 9006206
    Abstract: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: April 14, 2015
    Assignees: Rosetta Genomics Ltd., Yeda Research and Development Company Ltd.
    Inventors: Moshe Oren, Nina Raver-Shapira, Efi Marciano, Yael Spector
  • Patent number: 9000142
    Abstract: There is disclosed a photocleavable sense-antisense nucleobase polymer complex capable of modulating gene expression comprising an unnatural antisense nucleobase polymer that targets an mRNA, and a photocleavable sense nucleobase polymer noncovalently bound to the antisense nucleobase polymer, wherein the photocleavable sense nucleobase polymer comprises a plurality of nucleobase polymers connected by a photocleavable linkage. There is also disclosed a method for controlling the time and spatial position of gene expression comprising selecting a target mRNA, introducing the photocleavable sense-antisense nucleobase polymer complex into a cell, and selectively irradiating the cell with light.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: April 7, 2015
    Assignee: Syntrix Biosystems, Inc.
    Inventor: John A. Zebala
  • Patent number: 8999950
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating alcoholism in humans).
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: April 7, 2015
    Assignee: Protiva Biotherapeutics Inc.
    Inventors: Ian MacLachlan, Amy C. H. Lee
  • Patent number: 8999642
    Abstract: The invention provides methods for controlling the density of different molecular species on the surface of a solid support. A first mixture of different molecular species is attached to a solid support under conditions to attach each species at a desired density, thereby producing a derivatized support having attached capture molecules. The derivatized support is treated with a second mixture of different molecular species, wherein different molecular species in the second mixture bind specifically to the different capture molecules attached to the solid support. One or more of the capture molecules can be reversibly modified such that the capture molecules have a different activity before and after the second mixture of molecular species are attached. In particular embodiments, the different molecular species are nucleic acids that are reversibly modified to have different activity in an amplification reaction.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: April 7, 2015
    Assignee: Illumina, Inc.
    Inventors: Andrea Sabot, Roberto Rigatti, Min-Jui Richard Shen
  • Patent number: 8999944
    Abstract: The present invention relates to screening assays for the identification of agents that can modify the interaction of thioredoxin interacting protein (TXNEP) on thioredoxin (TRX)5 preferably by inhibiting TXNIP downregulation of TXR. The use of such compounds, including the disclosed siRNA and antibodies against TXNIP, is contemplated for therapeutic or prophylactic treatment of vascular disease conditions, particularly those associated with pro-inflammatory activity of the TNF-ASK1-JNK-p38 pathways.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: April 7, 2015
    Assignee: University of Rochester
    Inventor: Bradford C. Berk
  • Patent number: 9000144
    Abstract: In Caenorhabditis elegans, lin-4 and let-7 encode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed RNAs, termed microRNAs, (miRNAs), exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRAN, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: April 7, 2015
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Thomas Tuschl, Mariana Lagos-Quintana, Winfried Lendeckel, Jutta Dammann, Reinhard Rauhut